Generated by AI
CareDx, Inc. is a transplant diagnostics and healthcare technology company focused on improving care for organ and stem cell transplant recipients. Its current offerings include AlloSure donor-derived cell-free DNA tests for kidney, heart, and lung transplantation, AlloMap gene-expression profiling for heart transplant patients, and HeartCare, which combines complementary biological insights to support transplant monitoring. The company also provides HistoMap Kidney for analyzing rejection in biopsy tissue and AlloHeme for monitoring relapse in certain blood cancers. Its broader portfolio includes high-resolution human leukocyte antigen typing, chimerism testing, cell-therapy monitoring, and transplant-management software such as Ottr and MedActionPlan. CareDx serves transplant centers, clinicians, laboratories, and patients by combining molecular diagnostics, laboratory services, and digital tools. Through this integrated model, CareDx occupies a specialized role in precision medicine, supporting post-transplant surveillance, rejection assessment, treatment decisions, and long-term organ health.
Website8000 Marina Boulevard
Brisbane, CA, 94005
United States
The latest articles about CDNA.
The average of price targets set by Wall Street analysts indicates a potential upside of 28.1% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Summary of Oct 30's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Investors talking about CDNA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.